Printer Friendly

BARD REQUESTS IDE FOR HYLAGEL-MUSCLE

 BARD REQUESTS IDE FOR HYLAGEL-MUSCLE
 RIDGEFIELD, N.J., Feb. 18 /PRNewswire/ -- Biomatrix, Inc.


(NASDAQ: BIOX) reported today that the Bard Urological Division of C.R. Bard, Inc. submitted a request for an Investigational Device Exemption (IDE) to the Food and Drug Administration (FDA). This submission requests authorization to commence human clinical trials on Hylagel(R)- Muscle, an injectable gel for the treatment of urinary incontinence, manufactured by Biomatrix, Inc.
 Urinary stress incontinence is a condition which is estimated to affect over three million people in the U.S. alone. Hylagel-Muscle consists of hylan gel, a chemically cross-linked form of a naturally occurring carbohydrate, called hyaluronan. Hylagel-Muscle is injected directly into the urinary sphincter in order to increase pressure on the urethra and stem the uncontrolled flow of urine. Currently available treatment alternatives include corrective surgery or adult diapers.
 Based on contractual agreements between the companies, Bard will fund and direct the clinical trials. Biomatrix will manufacture the product and receive a royalty on sales. Bard has exclusive marketing rights to the product on a world-wide basis.
 Biomatrix develops advanced biomaterials for use in therapeutic medical applications and skin care products based on hylan technology. Hylans, patented by Biomatrix, are chemically modified forms of hyaluronan. The company is headquartered in Ridgefield, N.J.
 -0- 2/18/92
 /CONTACT: Melissa Mack of Howard J. Rubenstein Associates, Inc., 212-489-6900, for Biomatrix/
 (BIOX) CO: Biomatrix Inc. ST: New Jersey IN: MTC SU:


KD-KW -- NY074 -- 9981 02/18/92 13:19 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 18, 1992
Words:247
Previous Article:GENCORP ANTICIPATES IMPROVED EARNINGS IN FIRST QUARTER
Next Article:U.S. HEALTHCARE ANNOUNCES CASH DIVIDEND
Topics:


Related Articles
Bard begins XT coronary stent clinical trial.
Bard's Carotid Stent Obtains CE Mark.
Bard Announces Endologix Agreement for AAA Device.
Endologix Inc. Initiates U.S. Clinical Trials and Launches Product in Europe.
Biomatrix Announces FDA Approval to Begin Pivotal Clinical Trials for Surgical Adhesion Prevention Product.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters